Collaboration, License, Co-Promotion and Other Commercial Agreements (Tables)

3 Months Ended

Mar. 31, 2020

Schedule of revenue attributable to transactions from collaboration and license arrangements


	Three Months Ended
	March 31,
Collaborative Arrangements Revenue	2020		2019
Linaclotide Collaboration Agreements:
Allergan (North America)	$	71,692	$	64,785
Allergan (Europe and other)		643		420
AstraZeneca (China, including Hong Kong and Macau)		332		—
Astellas (Japan)		479		—
Co-Promotion and Other Agreements:
Alnylam (GIVLAARI)		945		—
Other		354		947
Total collaborative arrangements revenue	$	74,445	$	66,152
Sale of API
Linaclotide License Agreements:
Astellas (Japan)	$	—	$	2,575
AstraZeneca (China, including Hong Kong and Macau)		5,498		—
Other		—		3
Total sale of API	$	5,498	$	2,578

Allergan

Table Text Blocks

Schedule of revenue attributable to transactions from collaboration and license arrangements

The Company recognized collaborative arrangements revenue from the Allergan collaboration agreement for North America during the three months ended March 31, 2020 and 2019 as follows (in thousands):


	Three Months Ended
	March 31,
	2020		2019
Collaborative arrangements revenue related to sales of LINZESS in the U.S.	$	71,142	$	64,293
Royalty revenue		550		492
Total collaborative arrangements revenue	$	71,692	$	64,785

Schedule of amount recorded by the Company for share of net loss related to collaborative arrangement

The following table presents the amounts recorded by the Company for commercial efforts related to LINZESS in the U.S. in the three months ended March 31, 2020 and 2019 (in thousands):


	Three Months Ended
	March 31,
	2020		2019
Collaborative arrangements revenue related to sales of LINZESS in the U.S.⁽¹⁾	$	71,142	$	64,293
Selling, general and administrative costs incurred by the Company⁽¹⁾		(8,674)		(10,277)
The Company’s share of net profit	$	62,468	$	54,016

(1) Includes only collaborative arrangements revenue or selling, general and administrative costs attributable to the cost-sharing arrangement with Allergan. Excludes approximately $0.2 million and approximately $0.5 million for the three months ended March 31, 2020 and 2019, respectively, related to patent prosecution and patent litigation costs recognized in connection with the collaboration agreement with Allergan for North America.